Correspondence
Leukemia (2003) 17, 1199–1200. doi:10.1038/sj.leu.2402954
Questioning the aim of CML therapy in the era of Imatinib?
A M Carella1
1Department of Onco-Hematology, Division of Hematology and Bone Marrow Transplantation Unit, IRCCS 'Casa Sollievo della Sofferenza', San Giovanni Rotondo (FG), Italy
Correspondence: Dr AM Carella, Department of Onco-Hematology, Division of Hematology and Bone Marrow Transplantation Unit, IRCCS 'Casa Sollievo della Sofferenza', San Giovanni Rotondo (FG), Italy
Received 8 January 2003; Accepted 14 February 2003.
